Canonico et al. performed a multicentre case-control study involving post-menopausal women aged 45 -70 years old to assess the impact of the route of estrogen administration on venous thromboembolism (VTE) risk. The collected data confirmed that oral estrogen therapy significantly increases the VTE risk in post-menopausal women, whereas there was no associated risk with transdermal estrogen. Additionally, the use of micronised progesterone was found to be safe with respect to thrombotic risk. This study emphasises the importance of considering the route of hormone administration, enabling women and healthcare practitioners to be better informed in the management of menopausal symptoms.